Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the Netherlands / NCT06178822
Recruiting Observational

Towards Novel BIOmarkers to Diagnose SEPsis on the Emergency Room

NCT06178822 · tracked via the Priya Life Science Netherlands tracker
Sponsor
Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)
Phase
Observational
Started
2022-10-25
Last updated
2025-10-02

Condition(s) studied

SepsisSeptic ShockSepsis, SevereInfectionsInfection ViralInfection, BacterialInfections, Respiratory

Investigational drug(s) / intervention(s)

No intervention

No intervention: There is no intervention

Study summary

Objectives:

1. To compare the immune response of patients with or without sepsis presenting to the ED with a(n) (suspected) infection.
2. To determine immune response aberrations that are associated with an increased risk of developing sepsis in patients presenting to the ED with a(n) (suspected) infection without sepsis.
3. To determine the long term cognitive and physical sequelae of sepsis after admission.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age 18 years or higher * Presentation at the Emergency Department (ED) * Clinical suspicion of infection or earlier confirmed infection * Modified Early Warning Score (MEWS) of 2 or higher Exclusion Criteria: * No informed consent given

Primary outcome measure(s)

Trial sites (3)

FacilityCityRegionStatus
Flevoziekenhuis Almere Stad Flevoland Not Yet Recruiting
Amsterdam UMC, location VUMC Amsterdam North Holland Recruiting
Amsterdam UMC, location AMC Amsterdam North Holland Recruiting

More Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC) trials in the Netherlands

Confocal Laser Endomicroscopy VERification Recruiting

Other trials for the same condition

X-linked Moesin Associated Immunodeficiency Recruiting
Molecular Culture for the Diagnosis of Pediatric Sepsis Recruiting
Long Term Effects of BCG Vaccination on Infectious and Immune Mediated Diseases Active, not recruiting
A Study to Learn About How Safe BAY 3389934 is, Its Suitable Dose, and How it Affects the Participants With Sepsis Induced Coagulopathy Recruiting
Fluid Management and Individualized Resuscitation in Sepsis Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06178822 on ClinicalTrials.gov ↗ ← All trials in the Netherlands